Brief: NCI-Sponsored Study Shows Positive Data For Lucid Diagnostics' Esoguard® Esophageal Dna Test In Patients Without Symptomatic Gerd
24/04/2025 13:16
April 24 (Reuters) - Lucid Group Inc LCID.O: NCI-SPONSORED STUDY SHOWS POSITIVE DATA FOR LUCID DIAGNOSTICS' ESOGUARD® ESOPHAGEAL DNA TEST IN PATIENTS WITHOUT SYMPTOMATIC GERD Source text: ID:nPn7s8bCMa Further company coverage: LCID.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lucid Diagnostics
See all newsBrief: Lucid Diagnostics Begins Receiving Medicare Reimbursement For Esoguard® And Closes $15 Million Financing
Lucid Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Lucid Diagnostics Inc expected to post a loss of 7 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE- Lululemon, United Rentals, cannabis stocks
U.S. STOCKS ON THE MOVE- American Airlines, Pot stocks, Paramount Skydance